Comprehending Breast Cancer
Landscape of cancer genes and mutational processes in breast cancer
In a study published today in Nature, researchers describe nine new genes that drive the development of breast cancer. This takes the tally of all genes associated with breast cancer development to 40.
The team examined all the genes in the genomes of 100 cases of breast cancer. The mutated cancer-causing genes were different in different cancer samples, indicating that breast cancer is genetically very diverse. Understanding the consequences of this diversity will be important in progressing towards more rational treatment.
Changes to DNA lie behind all cases of cancer. Cancer develops as a result of mutations — called somatic mutations — that are acquired during a person’s lifetime. Driver mutations, which occur in cancer genes, are a small subset of somatic mutations that drive the development of cancer.
“Breast cancer is the most common cancer in women,” explains Dr Patrick Tarpey, first author from the Wellcome Trust Sanger Institute. “To identify new cancer genes that lead to the development of breast cancer, we searched for driver mutations in over 21,000 genes, and found evidence for nine new cancer genes involved in the development of this cancer.”
These genome analyses provide a direct survey of the landscape of driver mutations in breast cancer. The team found driver mutations were present in at least 40 different cancer genes. Most individual cancers had different combinations of mutated cancer genes, demonstrating the substantial genetic diversity in breast cancer.
“In 28 cases we found only a single driver, but the maximum number of driver mutations in an individual cancer was six,” says Professor Mike Stratton, lead author and Director of the Wellcome Trust Sanger Institute. “We found that breast cancer can be caused by more than 70 different combinations of mutations.
“If we consider three breast cancers, each with four driver mutations: they might share none of those driver mutations — so each is a different genetic ‘animal’. They are different cancers driven by different genes. We need to classify them as carefully as we can. This study is a step towards that goal.”
“One of the most striking things about breast cancer is how it progresses differently in each patient and how each patient responds differently to therapy,” explains Professor Andy Futreal, until recently, Head of Cancer Genomics at the Wellcome Trust Sanger Institute and currently an Honorary Faculty Member at the Institute. “Our results can help us to understand these differences.”
Our genomes are scarred by decades of continual assault that leave mutations scattered though our DNA. This is the most comprehensive study thus far of mutations in breast cancers, discovering nine new mutated genes that cause breast cancer, and revealing the full diversity of the driving events that convert normal breast cells into breast cancers.
“The picture is certainly more complicated than we would have wanted, but as with many other things knowledge is our strongest weapon. These comprehensive insights reveal the faulty wiring of the cellular circuit board that causes cells to behave as cancers. Understanding our enemy at this level of detail will allow us to take more rational approaches to therapy, to understand why some cancers respond to drugs and others do not, and direct us to new vulnerabilities to be exploited in new treatments,” adds Professor Stratton.
On the Net: